Amneal Pharmaceuticals, Inc. AMRX Subtotal therapeutic classes — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported subtotal therapeutic classes — net revenue of $133.27M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue increased by 23.1% year-over-year, from $108.3M to $133.27M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s subtotal therapeutic classes — net revenue has grown at a 12.2% compound annual growth rate (CAGR), from $374.12M to $528.01M.
- What does subtotal therapeutic classes — net revenue mean?
- This metric represents the total net revenue generated from the company's specific therapeutic product categories within its portfolio. It reflects the market demand and commercial performance of these specialized pharmaceutical offerings, excluding returns, discounts, and allowances. Tracking this revenue stream provides insight into the growth trajectory and competitive positioning of the company's core therapeutic focus areas.